Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Telix Pharmaceuticals Limited ADR (TLX)

Telix Pharmaceuticals Limited ADR (TLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,628,801
  • Shares Outstanding, K 338,763
  • Annual Sales, $ 516,680 K
  • Annual Income, $ 32,930 K
  • EBIT $ 0 M
  • EBITDA $ 59 M
  • 60-Month Beta 0.60
  • Price/Sales 4.26
  • Price/Cash Flow 65.07
  • Price/Book 6.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.03
  • Number of Estimates 1
  • High Estimate 0.03
  • Low Estimate 0.03
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.31 +6.16%
on 01/13/26
8.15 -4.79%
on 12/24/25
-0.58 (-6.95%)
since 12/16/25
3-Month
7.31 +6.16%
on 01/13/26
11.00 -29.45%
on 10/27/25
-3.10 (-28.55%)
since 10/16/25
52-Week
7.31 +6.16%
on 01/13/26
30.36 -74.44%
on 02/24/25
-8.24 (-51.50%)
since 01/16/25

Most Recent Stories

More News
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options...

TLX : 7.76 (+4.44%)
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX

NEW YORK , Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action...

TLX : 7.76 (+4.44%)
TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive...

TLX : 7.76 (+4.44%)
Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed...

TLX : 7.76 (+4.44%)
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman

Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline

TLX : 7.76 (+4.44%)
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact The Gross Law Firm about pending Class Action - TLX

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).

TLX : 7.76 (+4.44%)
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Jan. 7, 2026 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix...

TLX : 7.76 (+4.44%)
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Jan. 6, 2026 /PRNewswire/ --  The Law Offices of Frank R. Cruz announces that investors with losses related to Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: ...

TLX : 7.76 (+4.44%)
TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , Jan. 6, 2026 /PRNewswire/ --

TLX : 7.76 (+4.44%)
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman

Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline

TLX : 7.76 (+4.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Th company is developing a portfolio of clinical and commercial stage products which aims to address significant...

See More

Key Turning Points

3rd Resistance Point 7.98
2nd Resistance Point 7.89
1st Resistance Point 7.82
Last Price 7.76
1st Support Level 7.66
2nd Support Level 7.57
3rd Support Level 7.50

See More

52-Week High 30.36
Fibonacci 61.8% 21.55
Fibonacci 50% 18.84
Fibonacci 38.2% 16.12
Last Price 7.76
52-Week Low 7.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar